Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study

被引:0
|
作者
Morschhauser, Franck [1 ]
Bishton, Mark [2 ]
Eyre, Toby A. [3 ]
Bachy, Emmanuel [4 ]
Cartron, Guillaume [5 ]
Ysebaert, Loic [6 ]
Bobillo, Sabela [7 ]
Gutierrez, Norma C. [8 ]
Budde, Elizabeth [9 ]
Fox, Christopher P. [2 ]
Knapp, Andrea [10 ]
Yaqub, Manejeh [11 ]
Wei, Michael C. [11 ]
O'Hear, Carol [11 ]
Li, Haocheng [12 ]
Purev, Enkhtsetseg [11 ]
Townsend, William [13 ]
机构
[1] Univ Lille, Grp Res Formes Injectables & Technol Associees, Lille, France
[2] Nottingham Univ Hosp NHS Trust, Nottingham, England
[3] Oxford Univ Hosp NHS Trust, Oxford, England
[4] Ctr Hosp Lyon Sud, Lyon, France
[5] CHU Montpellier, Montpellier, France
[6] CHU Toulouse, Toulouse, France
[7] Hosp Univ Valle de Hebron, Barcelona, Spain
[8] Hosp Univ Salamanca, Salamanca, Spain
[9] City Hope Natl Med Ctr, Duarte, CA USA
[10] F Hoffmann La Roche Ltd, Basel, Switzerland
[11] Genentech Inc, San Francisco, CA USA
[12] F Hoffmann La Roche Ltd, Mississauga, ON, Canada
[13] Univ Coll London Hosp BRC Clin Res Facil, London, England
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BSH22-PO58
引用
收藏
页码:105 / 106
页数:2
相关论文
共 50 条
  • [41] Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study
    Hawkes, Eliza A.
    Phillips, Tycel
    Budde, Lihua Elizabeth
    Santoro, Armando
    Saba, Nakhle S.
    Roncolato, Fernando
    Gregory, Gareth P.
    Verhoef, Gregor
    Offner, Fritz
    Quero, Cristina
    Radford, John
    Giannopoulos, Krzysztof
    Stevens, Don
    Thall, Aron
    Huang, Bo
    Laird, A. Douglas
    Sandner, Robin
    Ansell, Stephen M.
    TARGETED ONCOLOGY, 2021, 16 (06) : 761 - 771
  • [42] Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib/II Trial
    Diefenbach, Catherine
    Kahl, Brad S.
    Banerjee, Lalita
    McMillan, Andrew K.
    Miall, Fiona
    Briones, Javier
    Cordoba, Raul
    Hirata, Jamie
    Chang, YiMeng
    Musick, Lisa
    Abrisqueta, Pau
    BLOOD, 2019, 134
  • [43] Phase Ib/II trial of polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed/refractory follicular lymphoma: primary analysis of the full efficacy population
    Diefenbach, C. S.
    McMillan, A.
    Kahl, B. S.
    Miall, F.
    Banerjee, L.
    Briones, J.
    Cordoba, R.
    Abrisqueta, P.
    Hirata, J.
    Chang, Y.
    Musick, L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 113 - 114
  • [44] Initial results from an international study in relapsed/refractory aggressive non-Hodgkin's lymphoma to confirm the activity, safety and criteria for predicting response to lenalidomide monotherapy
    Wilzig, Thomas E.
    Reeder, Craig B.
    Polikoff, Jonathan
    Chowhan, Naveed M.
    Esseessee, Isaac
    Greenberg, Richard
    Patel, Hermant
    Vafai, Davood
    Wiernik, Peter H.
    Ervin-Haynes, Annette
    Pietronigro, Dennis
    Zeldis, Jerome B.
    Czuczman, Myron
    BLOOD, 2007, 110 (11) : 758A - 758A
  • [45] Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study
    Budde, Elizabeth L.
    Bartlett, Nancy L.
    Giri, Pratyush
    Schuster, Stephen J.
    Assouline, Sarit
    Yoon, Sung-Soo
    Fay, Keith
    Matasar, Matthew J.
    Gutierrez, Norma C.
    Marlton, Paula
    Dreyling, Martin
    Yoon, Dok Hyun
    Hess, Georg
    Radford, John
    Wiebking, Volker
    Yin, Shen
    Cybulski, Eva
    Turner, David C.
    Huang, Huang
    Zhou, Mingzhu
    Penuel, Elicia
    Wei, Michael C.
    Sehn, Laurie H.
    BLOOD, 2022, 140 : 3753 - 3755
  • [46] Fotemustine IN COMBINATION with BORTEZOMIB and DEXAMETHASONE: Encouraging PRELIMINARY RESULTS FROM A PHASE II STUDY On Relapsed REFRACTORY MYELOMA PATIENTS.
    Corso, Alessandro
    Mangiacavalli, Silvia
    Cocito, Federica
    Pascutto, Cristiana
    Astori, Cesare
    Varettoni, Marzia
    Orlandi, Ester
    Zappasodi, Patrizia
    Rizzi, Silvia
    Ambaglio, Ilaria
    Lazzarino, Mario
    Cazzola, Mario
    BLOOD, 2010, 116 (21) : 1252 - 1252
  • [47] A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory B-and T-Cell Lymphomas
    Mehta-Shah, Neha
    Moskowitz, Alison J.
    Lunning, Matthew A.
    Lynch, Peggy
    Scheuerman, Mark
    Minnal, Veenna
    Galasso, Natasha
    Kumar, Anita
    Gerecitano, John
    Zelenetz, Andrew D.
    Hamlin, Paul A.
    Noy, Ariela
    Matasar, Matthew J.
    Palomba, Maria Lia
    Younes, Anas
    Schaffer, Wendy
    Grewal, Ravinder
    Rademaker, Jurgen
    Sauter, Craig S.
    Dahi, Parastoo B.
    Myskowski, Patricia
    Kheterpal, Meenal
    Dogan, Ahmet
    Pulitzer, Melissa
    Lubin, Lakeisha
    Tang, Laura
    Ganesan, Nivetha
    Ni, Ai
    Horwitz, Steven M.
    BLOOD, 2017, 130
  • [48] Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study
    Palomba, M. Lia
    Till, Brian G.
    Park, Steven I.
    Morschhauser, Franck
    Cartron, Guillaume
    Marks, Reinhard
    Shivhare, Mahesh
    Hong, Wan-Jen
    Raval, Aparna
    Chang, Alice C.
    Penuel, Elicia
    Popplewell, Leslie L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : E443 - E451
  • [49] Results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple mycloma
    Mahindra, A. K.
    Richardson, P. G.
    Hari, P.
    Laubach, J.
    Ghobrial, I. M.
    Schlossman, R. L.
    Weller, E.
    Munshi, N. C.
    Anderson, K. C.
    Raje, N. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [50] Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study
    Noriko Fukuhara
    Dai Maruyama
    Kiyohiko Hatake
    Hirokazu Nagai
    Shinichi Makita
    Kenjiro Kamezaki
    Toshiki Uchida
    Shigeru Kusumoto
    Junya Kuroda
    Chisako Iriyama
    Masamitsu Yanada
    Norifumi Tsukamoto
    Youko Suehiro
    Hironobu Minami
    Jose Garcia-Vargas
    Barrett H. Childs
    Masanobu Yasuda
    Shigeo Masuda
    Toshiaki Tsujino
    Yui Terao
    Kensei Tobinai
    International Journal of Hematology, 2023, 117 : 100 - 109